Anti-Cancer MAbS Global Market Report 2025

Description

Anticancer monoclonal antibodies (mAbs) are antibodies utilized in monoclonal antibody therapy with the aim of targeting and destroying cancer cells. These antibodies are designed to bind to specific proteins or chemicals found on the surface of cancer cells, thereby inhibiting the growth and spread of cancer.

The primary types of anti-cancer mAbs include murine antibodies, chimeric antibodies, humanized antibodies, and others. Murine antibodies are a specific category of monoclonal antibodies that are laboratory-made copies of a single antibody. These antibodies are produced by a single B cell and are derived from mice or rats. They are engineered to bind to a specific antigen. Anticancer mAbs find applications in various cancer types, including blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, among others. These antibodies are used in settings such as hospitals, research institutes, and other medical facilities.

The anti-cancer MABs market research report is one of a series of new reports from The Business Research Company that provides anti-cancer MABs market statistics, including anti-cancer MABs industry global market size, regional shares, competitors with an anti-cancer MABs market share, detailed anti-cancer MABs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer MABs industry. This anti-cancer MABs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-cancer mabs market size has grown rapidly in recent years. It will grow from $69.33 billion in 2024 to $76.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to increasing cancer incidence rates, growing understanding of cancer biology, rise in personalized medicine approaches, increased investment in research and development, growing patient awareness and demand.

The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $109.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to advancements in immunotherapy, increasing adoption of combination therapies, emergence of next-generation mAbs, global efforts to address cancer burden, expansion of patient access programs. Major trends in the forecast period include innovations in drug delivery technologies, integration of artificial intelligence in drug discovery, collaborations and partnerships in the pharma industry, advancements in biotechnology, car-t cell therapies.

The increasing incidence of cancer worldwide is expected to drive the growth of the anticancer monoclonal antibodies (mAbs) market. Cancer is a chronic disease that affects millions of individuals globally. Anticancer mAbs are designed to target specific proteins found on cancer cells, using genetically engineered versions of the immune system's antibodies to combat cancerous cells. With the rising prevalence of cancer, there is a growing demand for more effective therapies such as anticancer mAbs. For instance, according to a January 2022 report from PubMed, an estimated 1.9 million new cancer cases are anticipated globally, with 609,360 cancer-related deaths expected in the United States. Consequently, the increasing prevalence of cancer is a significant driver for the growth of the anticancer mAbs market.

The increasing number of clinical trials is expected to drive the growth of the anti-cancer monoclonal antibodies (mAbs) market in the future. A clinical trial is a research study that prospectively assigns individuals to one or more health-related interventions to assess the effects of those interventions on health-related biomedical or behavioral outcomes. Clinical trials have been instrumental in the development and refinement of anti-cancer mAbs, providing valuable insights into their safety, efficacy, and potential mechanisms of action. For instance, in May 2023, ClinicalTrials.gov, a platform for registering clinical trials, reported a total of 452,604 clinical trials in 2023, an increase from the 365,000 registered trials in 2021. Therefore, the growing number of clinical trials is contributing to the expansion of the anti-cancer mAbs market.

Product innovation is a prominent trend within the anticancer mAbs market, with major companies introducing more targeted and effective cancer treatments. For example, in May 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, launched PHESGO, a unique combination treatment for HER2-positive early breast cancer. PHESGO consists of two monoclonal antibodies, pertuzumab and trastuzumab, combined with the enzyme hyaluronidase. This subcutaneous injection, leveraging hyaluronidase, enhances mAbs absorption, allowing for subcutaneous administration rather than intravenous, offering patients a more convenient treatment option. Such innovative approaches demonstrate a commitment to developing advanced and patient-friendly therapies within the anticancer mAbs market.

Major players in the anti-cancer monoclonal antibodies (mAbs) market are strategically focusing on innovative strategies, such as conducting clinical trials, to establish a competitive advantage in the industry. Clinical trials are pivotal research studies that assess the safety and efficacy of novel treatments, medications, or devices in human subjects. For instance, in April 2023, Y-mAbs Therapeutics Inc., a prominent clinical biopharmaceutical company based in the United States, initiated a Phase I Trial for GD2-Targeted Radioimmunotherapy. This trial aims to evaluate the safety and effectiveness of GD2-SADA, a pre-targeted radioimmunotherapy (RIT), in treating specific GD2-positive solid tumors such as small cell lung cancer, sarcoma, and malignant melanoma. GD2-SADA follows a distinctive two-step procedure to administer radiation to tumor cells. Initially, the SADA protein attaches to GD2 proteins present on the surface of various solid tumors. Subsequently, the radioactive ligand 177Lu-DOTA is introduced, binding to the SADA protein and delivering radiation specifically to the tumor cells. This two-step approach is devised to limit radiation exposure to healthy tissues.

In June 2024, Merck & Co., Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.8 billion. This acquisition strengthens Merck's portfolio in immunology, especially with Prometheus's lead candidate, PRA023 (now referred to as MK-7240), a monoclonal antibody that targets TL1A, which is associated with autoimmune diseases such as ulcerative colitis and Crohn's disease. Prometheus Biosciences Inc. is a US-based clinical-stage biotechnology company specializing in anti-cancer monoclonal antibodies (mAbs).

Major companies operating in the anti-cancer mabs market report are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB .

North America was the largest region in the anti-cancer MAbS market in 2023. Asia Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-cancer mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anticancer mAbs market consists of sales of monoclonal antibody therapies such as avastin, Herceptin, keytruda, opdivo, darzalex, and perjeta. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Cancer MAbS Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-cancer mabs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-cancer mabs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-cancer mabs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Murine Antibodies; Chimeric Antibodies; Humanized Antibodies; Other Types
2) By Application: Blood Cancer; Breast Cancer; Lung Cancer; Melanoma; Colorectal Cancer; Liver Cancer; Other Applications
3) By End User: Hospitals; Research Institutes; Other End Users
Subsegments:
1) By Murine Antibodies: Murine IgG; Murine IgM; Other Murine Isotypes
2) By Chimeric Antibodies: Chimeric IgG; Chimeric IgM; Other Chimeric Isotypes
3) By Humanized Antibodies: Humanized IgG; Humanized IgM; Other Humanized Isotypes
4) By Other Types: Fully Human Antibodies; Bispecific Antibodies; Conjugated Antibodies; Other Novel Formats
Companies Mentioned: Amgen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r32985

1. Executive Summary

2. Anti-Cancer MAbS Market Characteristics

3. Anti-Cancer MAbS Market Trends And Strategies

4. Anti-Cancer MAbS Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anti-Cancer MAbS Growth Analysis And Strategic Analysis Framework

5.1. Global Anti-Cancer MAbS PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Anti-Cancer MAbS Market Growth Rate Analysis
5.4. Global Anti-Cancer MAbS Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Anti-Cancer MAbS Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Anti-Cancer MAbS Total Addressable Market (TAM)

6. Anti-Cancer MAbS Market Segmentation

6.1. Global Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Murine Antibodies
Chimeric Antibodies
Humanized Antibodies
Other Types
6.2. Global Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Cancer
Breast Cancer
Lung Cancer
Melanoma
Colorectal Cancer
Liver Cancer
Other Applications
6.3. Global Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutes
Other End Users
6.4. Global Anti-Cancer MAbS Market, Sub-Segmentation Of Murine Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Murine IgG
Murine IgM
Other Murine Isotypes
6.5. Global Anti-Cancer MAbS Market, Sub-Segmentation Of Chimeric Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chimeric IgG
Chimeric IgM
Other Chimeric Isotypes
6.6. Global Anti-Cancer MAbS Market, Sub-Segmentation Of Humanized Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Humanized IgG
Humanized IgM
Other Humanized Isotypes
6.7. Global Anti-Cancer MAbS Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fully Human Antibodies
Bispecific Antibodies
Conjugated Antibodies
Other Novel Formats

7. Anti-Cancer MAbS Market Regional And Country Analysis

7.1. Global Anti-Cancer MAbS Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Anti-Cancer MAbS Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Cancer MAbS Market

8.1. Asia-Pacific Anti-Cancer MAbS Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Cancer MAbS Market

9.1. China Anti-Cancer MAbS Market Overview
9.2. China Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Cancer MAbS Market

10.1. India Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Cancer MAbS Market

11.1. Japan Anti-Cancer MAbS Market Overview
11.2. Japan Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Cancer MAbS Market

12.1. Australia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Cancer MAbS Market

13.1. Indonesia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Cancer MAbS Market

14.1. South Korea Anti-Cancer MAbS Market Overview
14.2. South Korea Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Cancer MAbS Market

15.1. Western Europe Anti-Cancer MAbS Market Overview
15.2. Western Europe Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Cancer MAbS Market

16.1. UK Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Cancer MAbS Market

17.1. Germany Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Cancer MAbS Market

18.1. France Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Cancer MAbS Market

19.1. Italy Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Cancer MAbS Market

20.1. Spain Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Cancer MAbS Market

21.1. Eastern Europe Anti-Cancer MAbS Market Overview
21.2. Eastern Europe Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Cancer MAbS Market

22.1. Russia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Cancer MAbS Market

23.1. North America Anti-Cancer MAbS Market Overview
23.2. North America Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Cancer MAbS Market

24.1. USA Anti-Cancer MAbS Market Overview
24.2. USA Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Cancer MAbS Market

25.1. Canada Anti-Cancer MAbS Market Overview
25.2. Canada Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Cancer MAbS Market

26.1. South America Anti-Cancer MAbS Market Overview
26.2. South America Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Cancer MAbS Market

27.1. Brazil Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Cancer MAbS Market

28.1. Middle East Anti-Cancer MAbS Market Overview
28.2. Middle East Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Cancer MAbS Market

29.1. Africa Anti-Cancer MAbS Market Overview
29.2. Africa Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Cancer MAbS Market Competitive Landscape And Company Profiles

30.1. Anti-Cancer MAbS Market Competitive Landscape
30.2. Anti-Cancer MAbS Market Company Profiles
- 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Cancer MAbS Market Other Major And Innovative Companies

31.1. Johnson & Johnson
31.2. Novartis AG
31.3. Merck & Co. Inc.
31.4. Spectrum Pharmaceuticals Inc.
31.5. AstraZeneca plc.
31.6. Pfizer Inc.
31.7. Gilead Sciences Inc.
31.8. Bayer HealthCare
31.9. ImmunoGen Inc.
31.10. Genentech Inc.
31.11. AbbVie Inc.
31.12. Takeda Pharmaceuticals
31.13. Seattle Genetics
31.14. Regeneron Pharmaceuticals
31.15. Celgene

32. Global Anti-Cancer MAbS Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Cancer MAbS Market

34. Recent Developments In The Anti-Cancer MAbS Market

35. Anti-Cancer MAbS Market High Potential Countries, Segments and Strategies

35.1 Anti-Cancer MAbS Market In 2029 - Countries Offering Most New Opportunities
35.2 Anti-Cancer MAbS Market In 2029 - Segments Offering Most New Opportunities
35.3 Anti-Cancer MAbS Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer